Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Gene expression profiling in MDS and AML: potential and future avenues

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Identification of two distinct pathways of human myelopoiesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A programmed wave of uridylation-primed mRNA degradation is essential for meiotic progression and mammalian spermatogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  • K Theilgaard-Mönch
  • J Boultwood
  • S Ferrari
  • K Giannopoulos
  • J M Hernandez-Rivas
  • A Kohlmann
  • M Morgan
  • Bo T Porse
  • E Tagliafico
  • C M Zwaan
  • J Wainscoat
  • M M Van den Heuvel-Eibrink
  • K Mills
  • L Bullinger
View graph of relations
Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.
Original languageEnglish
JournalLeukemia
Volume25
Issue number6
Pages (from-to)909-20
Number of pages12
ISSN0887-6924
DOIs
Publication statusPublished - 2011

    Research areas

  • Classification, Forecasting, Gene Expression Profiling, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

ID: 33286188